Tresiba

Tresiba

Novo Nordisk

Tresiba (insulin degludec injection) is a long-acting insulin used to improve blood glucose in adults and children 1 year of age and older with diabetes. Tresiba is delivered via vial and syringe or pen. Tresiba first appears in the blood stream 1 hour after subcutaneous injection. It is also available as U-200, a different concentration of insulin, but only as an insulin pen.


Features


Specs

Insulin Type:
Long-acting
Generic Name:
Insulin degludec
Delivery:
Syringe (U-100 only) or pen (U-100 and U-200)
Form:
Analog
Concentrations:
U-100 and U-200
Onset:
1 hour
Peak:
No peak
Duration:
At least 42 hours